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Biosensors
better understand the normal and pathological path¬
ways of several metabolites in medical care and will
find many applications in the study of their altera¬
tion or restoration to normal values.
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Introduction
Electrochemical biosensors and, in particular,
enzyme-based sensors have found wide applica¬
tions in the measurement of specific species in com¬
plex media such as biological, industrial and
environmental samples. Although relatively limited
in number, analytical equipment using such bio¬
sensors has been developed in the I '.S.A., Kurope
and Japan and are commercially available for such
applications. Since the first publication bv Clark &
Lyons | I |, one of the main challenges for such bio¬
sensors has been, and still is, their implantation in
vivo, either for continuously monitoring metabolites
or drugs, especially in intensive care units, or for
controlling artificial organs, such as insulin pumps
used by diabetic patients |2|, or haemodialysis
Abbreviation used: ( i( )x, glucose oxidase.
units. For more than a quarter of a century a large
number of publications, review, books, workshops
and symposia have been devoted to this topic. Seen
from outside, no apparent success or improvement
has been obtained, since no operating implantable
biosensor is presently available. This report will
attempt to present some of the real improvements
obtained and the various strategies recently
developed, mainly illustrated with European ex¬
amples. Indeed, a biomedical engineering European
concerted action (BME-COMAC) has been estab¬
lished since January 1989 on 'Chemical Sensors for
in vivo Monitoring', under the leadership of A. P. F.
Turner.
Biosensors: principles
Biosensors mav be variously defined but the name
is usually restricted to chemical sensors monitoring
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species using biological molecules or reactions for
their selective molecular recognition procedure.
Thus pi I or oxygen sensors, when implanted in
vivo, are preferably called 'bioprobes1 instead of
'biosensors' [3].
All biosensors are analytical devices in which
a molecular recognition system is closely associated
with or integrated to a system transforming this
chemical information into an electric signal [4]: (1)
the sensor selectivity is based on a biological
molecular recognition system: immobilized or
retained enzymes, antibodies or membrane recep¬
tors, or biologically integrated systems (plant or
animal tissues, micro-organisms); today most
implanted biosensors use immobilized enzymes; (2)
a physico-chemical transducer or detector monitors
the molecular recognition system: it may be electro¬
chemical (potentiometric, amperometric, coulo-
metric, ionic conductivity, surface charge-field effect
transistor), thermal or calorimetric (enthalpic) or
mass specific (piezoelectric crystal); we will restrict
this paper to the first type of detectors, i.e. electro¬
chemical, since they are the most widely used, and,
even more specifically, to amperometric enzyme-
based sensors.
Operating properties of biosensors
Although the detailed and accurate modelling of
biosensors is not always available, their behaviour is
generally understood, their rate-limiting steps con¬
trolled and their operating parameters well defined.
Three types of operating parameters are of import¬
ance when these biosensors are used for clinical
analysis in vitro: ( 1 ) analytical parameters charac¬
terize their patterns as analytical tools (background
signal, sensitivity, linear range, response time, preci¬
sion, selectivity, sensor life-time and sensor/sample
size); (2) signal-controlling parameters may be
either physical (local hydrodynamics, membrane
permeability, temperature), chemical (pll, buffer
capacity, ionic force, cofactor concentration level) or
biological (concentration level of molecular recogni¬
tion species) or, finally, the sample composition
itself, i.e. the level of interferents or inhibitors for
molecular recognition or transducer reactions; and
(3) sensor management methodologies include the
calibration procedure but also the evaluation of
the above-mentioned analytical parameters.
As these operating parameters may be easily
controlled when experiments are made in vitro,
such devices have proven reasonably reliable. Such
evaluation in vitro enables the selection of sensors
presenting characteristics suitable for each applica¬
tion in vivo. Nevertheless, conditions of such evalu¬
ation in vitro have to be defined in order to
approach actual environmental conditions in vivo.
Evaluation in vivo is even more complex
since, besides the choice of animal model, site and
method of sensor implantation, procedures have to
be found for modifying the metabolite level in such
a way that analytical performance of these sensors
can be determined accurately during extended
periods of operation. These operating parameters
may not be directly measurable (for example, back¬
ground signal, calibration, selectivity, influence of
local hydrodynamic conditions, etc.) and specific
difficulties may be encountered (e.g. miniaturization,
maximum of linear range, site of implantation,
clotting on outer membrane, inflammatory and
immune reactions to the implant, sterilization
procedure, etc.).
Strategies recently developed for in
vivo glucose sensors
The most widely studied type of implanted bio¬
sensor is definitely the glucose one. It is based upon
the /3-n-glucose oxidation by oxygen in the
presence of /3-n-glucose oxidase (GOx). Three
major strategies have been developed and tested on
short-term animal or human experiments [5]: (1)
cathodic detection of oxygen depletion by GOx in
the presence of glucose, using a specially designed
electrode for restricting oxygen partial pressure
dependence of the response in blood vessels
(Gough et al., San Diego, U.S.A.); (2) anodic detec¬
tion of hydrogen peroxide produced by GOx in the
presence of glucose: after the pioneer work of
Shichiri [6], several groups have developed similar
strategies (Ege, Copenhagen, DK; Fischer et al.,
Karlsburg, G.D.R.; Koudelka et al., Neuchatel,
Switzerland; Pfeiffer et al., Ulm, F.R.G.; Reach et al.,
Paris; Vadgama et al., Manchester, U.K.); and (3)
anodic detection of GOx reduced by glucose, using
ferrocene-type mediators (Pickup et al., London,
U.K.).
These strategies may be discussed together
with specific problems for in vivo glucose sensors:
(1) miniaturization of sensors using needle-type
geometries suggested by Shichiri et al. [6, 7]; (2)
deposition of active enzyme layers, using the />-
benzoquinone covalent immobilization procedure
or glutaraldehyde reticulation [7, 8]; (3) choice of
the site of implantation, i.e. vascular or subcuta¬
neous [9] ; (4) calibration procedure, i.e. determina¬
tion of background signal and sensitivity in vivo 15,
7]; and (5) biocompatibility assessments.
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These examples demonstrate the importance
of a multidisciplinary approach of in vivo chemical
sensors and of a tight collaboration between
physico-chemists (involved in, for example, analy¬
sis, electrochemistry, polymer science) and clini¬
cians (in the fields of diabetology, surgery and
biomaterial science) to solve the numerous prob¬
lems and difficulties encountered. They also show
that significant improvements have been obtained
allowing short-term in vivo implantation, but that
very difficult problems have arisen for controlling
interactions between biosensor and tissue, i.e.
modifications of the sensor by the tissue (e.g.
clotting of the external membrane or layer) as well
as modifications of the tissue by the sensor (e.g.
toxicity, inflammatory and immune reactions), both
reactions being usually described as biocompati-
bility of the implant.
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Problems of clinical data interpretation
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Biosensors offer the prospect of decentralized and,
where necessary, continuous monitoring of a wide
range of biochemically important analytes. They
constitute a means of formatting a biological recog¬
nition molecule in an immobilized, reusable form
and, more particularly, one which is characterized
by structural simplicity and reagent economy as
well as by the functional convenience resulting from
close juxtaposition to the transducer element.
Though much work has gone into the charac¬
terization of the biolayer and its transducer inter¬
face, comparatively little attention has been paid to
the external interface between the device and the
surrounding biomatrix. The consequent lack of
detailed knowledge on this aspect has been a signifi¬
cant impediment to optimum clinical use and,
therefore, ultimately to reliable data interpretation.
Interactions of the biosensor and its bio-
environment can be subdivided into those due to: (i)
solution variables; (ii) responses from colloid- and
cell-containing fluids; and (iii) a concerted tissue
response able to fundamentally change the nature of
a biosensor implantation site. These constitute a
hierarchy of increasingly complex problems which,
from initial contact, distort generated signals from
even the most sophisticated and well-fabricated
device. In the main, the final common pathway of
failure is a progressive loss in signal, the decay
kinetics of which are too poorly understood and
irreproducible to be either modelled accurately or
to serve as a firm basis for correcting signal drift in
an individual case. Also, superimposed upon this
monotonie decay may be fluctuations in signal size
over time-spans varying from minutes (Fig. 1) to
hours |1|; these can be difficult to separate into
analytical noise and true biological variation.
Specific delineation of the latter could potentiate the
diagnostic value of continuous monitoring bio¬
sensors, as there are undoubted changes in the vari¬
ability shown by individual biochemical parameters
in different disease states |2|. Discussion here will
include in vivo (),- and ion-selective electrodes,
1991
